1. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
- Author
-
Kindler T, Breitenbuecher F, Marx A, Hess G, Gschaidmeier H, Gamm H, Kirkpatrick CJ, Huber C, and Fischer T
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzamides, Bone Marrow pathology, Cytarabine administration & dosage, Daunorubicin administration & dosage, Disease Progression, Drug Resistance, Neoplasm, Exons genetics, Humans, Imatinib Mesylate, Leukemia, Myeloid, Acute enzymology, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute pathology, Male, Middle Aged, Neoplasm Proteins genetics, Neoplastic Stem Cells pathology, Proto-Oncogene Proteins c-kit genetics, Receptors, Platelet-Derived Growth Factor antagonists & inhibitors, Receptors, Platelet-Derived Growth Factor genetics, Recurrence, Remission Induction, Salvage Therapy, Anemia, Refractory drug therapy, Anemia, Refractory, with Excess of Blasts drug therapy, Antineoplastic Agents therapeutic use, Enzyme Inhibitors therapeutic use, Leukemia, Myeloid, Acute drug therapy, Neoplasm Proteins antagonists & inhibitors, Piperazines therapeutic use, Proto-Oncogene Proteins c-kit drug effects, Pyrimidines therapeutic use
- Abstract
Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl(+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit(+) secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response lasting for more than 5 months was observed. Sequence analysis of exons 2, 8, 10, 11, and 17 of the c-Kit receptor did not reveal structural alterations as previously described in a subset of AML cases. This is the first report of complete remission achieved upon administration of imatinib mesylate in a patient with highly refractory, secondary AML.
- Published
- 2003
- Full Text
- View/download PDF